Mouse monoclonal antibodies generated from full length human cereblon: Detection of cereblon protein in patients with multiple myeloma

Xiu-Bao D Chang, Qinqin Xu, Yuexian Hou, Cynthia Li, Ye Xu, Alexander Keith Stewart

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Immunomodulatory drugs (IMiDs) are profoundly active compounds in the treatment of patients with multiple myeloma (MM). However, despite the fact that treatment with IMiDs has dramatically improved survival for patients with MM, the majority of MM patients develop IMiDs resistance over time. We have found that expression of functional cereblon is required for IMiDs’ action. In addition, it has been reported that cells expressing high levels of cereblon are resistant to proteasome inhibitor, implying that patients with high levels of cereblon should be resistant to proteasome inhibitor. If the above conclusions are correct, cereblon could be considered as a biomarker to determine which standard regimens should be used to treat patients with MM. Unfortunately, the conclusions mentioned above have not been clinically confirmed. In order to confirm these conclusions, we have generated three highly specific mouse monoclonal antibodies (mAbs) against full-length human cereblon. These mAbs can be used to do western blot, immunoprecipitation and immunohistochemistry staining. In addition, their epitopes have been precisely determined and the peptides covering their epitopes completely blocked the antibody binding to cereblon in western blot analysis or in immunohistochemistry staining of MM patients’ specimens.

Original languageEnglish (US)
Article number1999
JournalInternational Journal of Molecular Sciences
Volume18
Issue number9
DOIs
StatePublished - Sep 17 2017

Fingerprint

Epitopes
Proteasome Inhibitors
Monoclonal antibodies
antibodies
Multiple Myeloma
mice
Monoclonal Antibodies
proteins
Proteins
Biomarkers
Antibodies
Peptides
Cells
staining
inhibitors
Western Blotting
Immunohistochemistry
Pharmaceutical Preparations
Staining and Labeling
biomarkers

Keywords

  • Cereblon (CRBN)
  • Epitope
  • Immunohistochemistry (IHC) staining
  • Immunomodulatory drugs (IMiDs)
  • Immunoprecipitation
  • Monoclonal antibody (mAb)
  • Multiple myeloma (MM)

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Mouse monoclonal antibodies generated from full length human cereblon : Detection of cereblon protein in patients with multiple myeloma. / Chang, Xiu-Bao D; Xu, Qinqin; Hou, Yuexian; Li, Cynthia; Xu, Ye; Stewart, Alexander Keith.

In: International Journal of Molecular Sciences, Vol. 18, No. 9, 1999, 17.09.2017.

Research output: Contribution to journalArticle

@article{32376c5a73e44287ab5aacad8e16b8a6,
title = "Mouse monoclonal antibodies generated from full length human cereblon: Detection of cereblon protein in patients with multiple myeloma",
abstract = "Immunomodulatory drugs (IMiDs) are profoundly active compounds in the treatment of patients with multiple myeloma (MM). However, despite the fact that treatment with IMiDs has dramatically improved survival for patients with MM, the majority of MM patients develop IMiDs resistance over time. We have found that expression of functional cereblon is required for IMiDs’ action. In addition, it has been reported that cells expressing high levels of cereblon are resistant to proteasome inhibitor, implying that patients with high levels of cereblon should be resistant to proteasome inhibitor. If the above conclusions are correct, cereblon could be considered as a biomarker to determine which standard regimens should be used to treat patients with MM. Unfortunately, the conclusions mentioned above have not been clinically confirmed. In order to confirm these conclusions, we have generated three highly specific mouse monoclonal antibodies (mAbs) against full-length human cereblon. These mAbs can be used to do western blot, immunoprecipitation and immunohistochemistry staining. In addition, their epitopes have been precisely determined and the peptides covering their epitopes completely blocked the antibody binding to cereblon in western blot analysis or in immunohistochemistry staining of MM patients’ specimens.",
keywords = "Cereblon (CRBN), Epitope, Immunohistochemistry (IHC) staining, Immunomodulatory drugs (IMiDs), Immunoprecipitation, Monoclonal antibody (mAb), Multiple myeloma (MM)",
author = "Chang, {Xiu-Bao D} and Qinqin Xu and Yuexian Hou and Cynthia Li and Ye Xu and Stewart, {Alexander Keith}",
year = "2017",
month = "9",
day = "17",
doi = "10.3390/ijms18091999",
language = "English (US)",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

TY - JOUR

T1 - Mouse monoclonal antibodies generated from full length human cereblon

T2 - Detection of cereblon protein in patients with multiple myeloma

AU - Chang, Xiu-Bao D

AU - Xu, Qinqin

AU - Hou, Yuexian

AU - Li, Cynthia

AU - Xu, Ye

AU - Stewart, Alexander Keith

PY - 2017/9/17

Y1 - 2017/9/17

N2 - Immunomodulatory drugs (IMiDs) are profoundly active compounds in the treatment of patients with multiple myeloma (MM). However, despite the fact that treatment with IMiDs has dramatically improved survival for patients with MM, the majority of MM patients develop IMiDs resistance over time. We have found that expression of functional cereblon is required for IMiDs’ action. In addition, it has been reported that cells expressing high levels of cereblon are resistant to proteasome inhibitor, implying that patients with high levels of cereblon should be resistant to proteasome inhibitor. If the above conclusions are correct, cereblon could be considered as a biomarker to determine which standard regimens should be used to treat patients with MM. Unfortunately, the conclusions mentioned above have not been clinically confirmed. In order to confirm these conclusions, we have generated three highly specific mouse monoclonal antibodies (mAbs) against full-length human cereblon. These mAbs can be used to do western blot, immunoprecipitation and immunohistochemistry staining. In addition, their epitopes have been precisely determined and the peptides covering their epitopes completely blocked the antibody binding to cereblon in western blot analysis or in immunohistochemistry staining of MM patients’ specimens.

AB - Immunomodulatory drugs (IMiDs) are profoundly active compounds in the treatment of patients with multiple myeloma (MM). However, despite the fact that treatment with IMiDs has dramatically improved survival for patients with MM, the majority of MM patients develop IMiDs resistance over time. We have found that expression of functional cereblon is required for IMiDs’ action. In addition, it has been reported that cells expressing high levels of cereblon are resistant to proteasome inhibitor, implying that patients with high levels of cereblon should be resistant to proteasome inhibitor. If the above conclusions are correct, cereblon could be considered as a biomarker to determine which standard regimens should be used to treat patients with MM. Unfortunately, the conclusions mentioned above have not been clinically confirmed. In order to confirm these conclusions, we have generated three highly specific mouse monoclonal antibodies (mAbs) against full-length human cereblon. These mAbs can be used to do western blot, immunoprecipitation and immunohistochemistry staining. In addition, their epitopes have been precisely determined and the peptides covering their epitopes completely blocked the antibody binding to cereblon in western blot analysis or in immunohistochemistry staining of MM patients’ specimens.

KW - Cereblon (CRBN)

KW - Epitope

KW - Immunohistochemistry (IHC) staining

KW - Immunomodulatory drugs (IMiDs)

KW - Immunoprecipitation

KW - Monoclonal antibody (mAb)

KW - Multiple myeloma (MM)

UR - http://www.scopus.com/inward/record.url?scp=85029668601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029668601&partnerID=8YFLogxK

U2 - 10.3390/ijms18091999

DO - 10.3390/ijms18091999

M3 - Article

C2 - 28926977

AN - SCOPUS:85029668601

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 9

M1 - 1999

ER -